Characterization of an Isotype-Dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Lim, Xiao Fang ^a   Jia, Qiang ^a   Khong, Wei Xin ^b,c   Yan, Benedict ^d   Premanand, Balraj ^a   Alonso, Sylvie ^b   Chow, Vincent T K ^b   Kwang, Jimmy ^a,b  

^a Animal Health Biotechnology   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 51; MONOCLONAL ANTIBODY 53; PROTEIN VP1; UNCLASSIFIED DRUG; CAPSID PROTEIN; VIRUS ANTIBODY; VIRUS RNA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CELL LOSS; CELL VACUOLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; EPITOPE MAPPING; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MOUSE; NERVE CELL; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PARALYSIS; PASSIVE IMMUNIZATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SPINAL PARALYSIS; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; CERCOPITHECUS; DRUG EFFECT; ENTEROVIRUS; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; SERODIAGNOSIS; VERO CELL; WESTERN BLOTTING;

HUMAN ENTEROVIRUS 71; MIRIDAE; MUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; EPITOPE MAPPING; EPITOPES; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN ISOTYPES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE HOMOLOGY, AMINO ACID; VERO CELLS;

EID: 84855963963     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029751     Document Type: Article

References (42)

1. Schmidt NJ, Lennette EH, Ho HH, (1974) An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 129: 304-309.
2. Hagiwara A, Tagaya I, Yoneyama T, (1978) Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology 9: 60-63.
3. Blomberg J, Lycke E, Ahlfors K, Johnsson T, Wolontis S, et al. (1974) Letter: New enterovirus type associated with epidemic of aseptic meningitis and-or hand, foot, and mouth disease. Lancet 2: 112.
4. Kennett ML, Birch CJ, Lewis FA, Yung AP, Locarnini SA, et al. (1974) Enterovirus type 71 infection in Melbourne. Bull World Health Organ 51: 609-615.
5. Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, et al. (1979) Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol 60: 329-340.
6. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I, (1982) Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol 71: 217-227.
7. Samuda GM, Chang WK, Yeung CY, Tang PS, (1987) Monoplegia caused by Enterovirus 71: an outbreak in Hong Kong. Pediatr Infect Dis J 6: 206-208.
8. Bible JM, Iturriza-Gomara M, Megson B, Brown D, Pantelidis P, et al. (2008) Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006. J Clin Microbiol 46: 3192-3200.
9. Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, et al. (1998) Fatal enterovirus 71 encephalomyelitis. J Pediatr 133: 795-798.
10. Liu CC, Tseng HW, Wang SM, Wang JR, Su IJ, (2000) An outbreak of enterovirus 71 infection in Taiwan, 1998: epidemiologic and clinical manifestations. J Clin Virol 17: 23-30.
11. Bendig JW, Fleming DM, (1996) Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales. Commun Dis Rep CDR Rev 6: R81-86.
12. Chang L-Y, (2008) Enterovirus 71 in Taiwan. Pediatrics & Neonatology 49: 103-112.
13. Wang LC, Tang SQ, Li YM, Zhao HL, Dong CH, et al. (2010) A comparison of the biological characteristics of EV71 C4 subtypes from different epidemic strains. Virol Sin 25: 98-106.
14. Hogle JM, Chow M, Filman DJ, (1985) Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229: 1358-1365.
15. Li C, Wang H, Shih SR, Chen TC, Li ML, (2007) The efficacy of viral capsid inhibitors in human enterovirus infection and associated diseases. Curr Med Chem 14: 847-856.
16. Tan CS, Cardosa MJ, (2007) High-titred neutralizing antibodies to human enterovirus 71 preferentially bind to the N-terminal portion of the capsid protein VP1. Arch Virol 152: 1069-1073.
17. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, et al. (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125: 61-68.
18. Tee KK, Lam TT, Chan YF, Bible JM, Kamarulzaman A, et al. (2010) Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J Virol 84: 3339-3350.
19. Dwyer JM, (1992) Manipulating the immune system with immune globulin. N Engl J Med 326: 107-116.
20. Kimura-Kuroda J, Yasui K, (1988) Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol 141: 3606-3610.
21. Geller TJ, Condie D, (1995) A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J Neurol Sci 129: 131-133.
22. Abzug MJ, Keyserling HL, Lee ML, Levin MJ, Rotbart HA, (1995) Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis 20: 1201-1206.
23. McKinney RE Jr, Katz SL, Wilfert CM, (1987) Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 9: 334-356.
24. Wang SM, Liu CC, (2009) Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther 7: 735-742.
25. Li X, Mao C, Ma S, Wang X, Sun Z, et al. (2009) Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 390: 1126-1128.
26. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, et al. (2011) Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29: 4362-4372.
27. Chang GH, Luo YJ, Wu XY, Si BY, Lin L, et al. (2010) Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virology Journal 7: 106.
28. Feinstein A, Munn EA, Richardson NE, (1971) The three-dimensional conformation of M and A globulin molecules. Ann N Y Acad Sci 190: 104-121.
29. Armstrong SJ, Outlaw MC, Dimmock NJ, (1990) Morphological studies of the neutralization of influenza virus by IgM. J Gen Virol 71 (Pt 10): 2313-2319.
30. Dimmock NJ, (1984) Mechanisms of neutralization of animal viruses. J Gen Virol 65 (Pt 6): 1015-1022.
31. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M, (2003) B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77: 2578-2586.
32. Salinas-Carmona MC, Perez-Rivera I, (2004) Humoral immunity through immunoglobulin M protects mice from an experimental actinomycetoma infection by Nocardia brasiliensis. Infect Immun 72: 5597-5604.
33. Roehrig JT, Nash D, Maldin B, Labowitz A, Martin DA, et al. (2003) Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases. Emerg Infect Dis 9: 376-379.
34. Foo DG, Alonso S, Chow VT, Poh CL, (2007) Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect 9: 1299-1306.
35. Xu F, Yan Q, Wang H, Niu J, Li L, et al. (2010) Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One 5: e11388.
36. Sigounas G, Harindranath N, Donadel G, Notkins AL, (1994) Half-life of polyreactive antibodies. J Clin Immunol 14: 134-140.
37. Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J, (2011) Display of VP1 on the Surface of Baculovirus and Its Immunogenicity against Heterologous Human Enterovirus 71 Strains in Mice. PLoS One 6: e21757.
38. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 27: 493-497.
39. Aarthi D, Ananda Rao K, Robinson R, Srinivasan VA, (2004) Validation of binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture vaccine. Biologicals 32: 153-156.
40. Bahnemann HG, (1975) Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol 47: 47-56.
41. Yokoyama WM, Christensen M, Santos GD, Miller D, (2006) Production of monoclonal antibodies. Curr Protoc Immunol Chapter 2: Unit 2 5.
42. Yokoyama WM, (2001) Monoclonal antibody supernatant and ascites fluid production. Curr Protoc Immunol Chapter 2: Unit 2 6.